Education
About Us
Working with TipRanks
Follow Us
Hansa Biopharma AB (SE:HNSA)
:HNSA
HNSA Stock Chart & Stats
kr33.92
-kr0.04(-0.17%)
At close: 4:00 PM EST
kr33.92
-kr0.04(-0.17%)
Day’s Range― - ―
52-Week Rangekr19.58 - kr42.98
Previous CloseN/A
Volume97.73K
Average Volume (3M)792.96K
Market Cap
kr3.45B
Enterprise Valuekr2.41B
Total Cash (Recent Filing)kr252.07M
Total Debt (Recent Filing)kr923.89M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Feb 05, 2026EPS Estimate
-1.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding101,763,220
10 Day Avg. Volume714,369
30 Day Avg. Volume792,961
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.18
Price to Sales (P/S)14.38
P/FCF Ratio-3.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr94.00Price Target Upside177.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In TransplantationPositive Phase 3 ConfIdeS topline results showing improved kidney function and reduced dialysis dependence indicate a clinically meaningful benefit that can drive adoption at transplant centers.
Financing And RunwayA directed share issue raised substantial capital, strengthening the company's financial position to support commercial rollout and continued clinical development.
Regulatory OutlookConditional approval in Europe combined with Key Opinion Leaders' view that regulators will focus on transplant-enabling efficacy supports the case for broader regulatory acceptance and potential FDA approval.
Bears Say
Analyst Valuation ImpactRemoval of the anti-GBM program from analyst models and a resulting price target reduction signal diminished growth expectations and investor reassessment.
Clinical Setback In Anti-GBMFailure of the anti-GBM Phase 3 study increases uncertainty around the program's therapeutic potential and future development plans.
Commercial Execution And Regional HeadwindsIdefirix sales running well below analyst expectations with pronounced weakness in key markets and a pause of regional programs point to near-term commercialization challenges that may pressure revenue.
Hansa Biopharma AB News
HNSA FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was kr19.58 and its highest was kr42.98 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr3.45B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Feb 05, 2026 which is in 16 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Oct 30, 2025. The company reported -kr1.75 earnings per share for the quarter, missing the consensus estimate of -kr1.737 by -kr0.013.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is -1.64.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr1.75 in its last earnings report, missing expectations of -kr1.737. Following the earnings report the stock price went down -11.027%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in SE:HNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
HNSA Stock 12 Month Forecast
Average Price Target
kr94.00
▲(177.12% Upside)
Technical Analysis
BioInvent International AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---